First-of-its-kind vaccine expands malaria protection for pregnant women

Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years

20-Aug-2024 - In a report a team led by investigators at the Malaria Research and Training Center (MRTC), Bamako, Mali; the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Sanaria Inc. describes the durable ...

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM

15-Aug-2024 - CureVac N.V.announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac’s first investigational cancer vaccine based on its proprietary second-generation mRNA backbone. It encodes a single fusion protein comprising ...

CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

17-Apr-2024 - CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...

Collaboration to develop vaccine against Helicobacter pylori

Core Facility Animal Models and start-up company Iguana cooperate

17-Oct-2023 - The Core Facility Animal Models (CAM) announces a new collaboration with drug discovery start-up Iguana Biotechnology GmbH (Iguana) to test their innovative vaccine candidate against Helicobacter pylori. Helicobacter pylori is one of the most common infectious diseases worldwide. It is a ...

Novel vaccine against a range of diseases caused by the Epstein-Barr virus

Start-up “EBViously“ announces first details of its EBV vaccine candidate

12-Apr-2023 - EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective preventive vaccine against a range of diseases caused by Epstein-Barr virus (EBV), including infectious ...

Use of Artificial Intelligence in Drug Development

WACKER, CordenPharma, LMU and HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives

03-Apr-2023 - Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma International GmbH have launched a project to accelerate the development of RNA-based drugs. The aim is to develop a new generation of lipid nanoparticles ...

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

09-Jan-2023 - CureVac N.V. announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK. The preliminary results generated by this ...

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

AstriVax to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection

29-Aug-2022 - Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs. The company will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer ...

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

19-Aug-2022 - CureVac N.V. announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to ...

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate

01-Apr-2022 - CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s ...